drugset / Trial / NCT03201185

Renin-angiotensin System Blockade Benefits in Clinical Evolution and Ventricular Remodeling After Transcatheter Aortic Valve Implantation (RASTAVI)

NCT03201185 ↗

Phase 4 Unknown 194 enrolled Hospital Clínico Universitario de Valladolid
RandomizedParallel-groupSingle-blindTreatment

Summary

The investigators aim to demonstrate that ramipril after transcatheter aortic valve implantation has benefits in terms of prognosis, cardiovascular events and ventricular remodeling (MRI).

Timeline

Start
2018-02-10
Primary completion
2021-08-13
Completion
2023-08

Outcome

Missed primary endpoint

paper The primary end point occurred in 10.6% in the ramipril group versus 12% in the control group (P=0.776) PMID 39291483 ↗

paper did not meet the primary end point PMID 39291483 ↗

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Ramipril Small molecule 10 mg —

Indications

No indication recorded.